Last updated: February 9, 2026
What is the current status of clinical trials for certolizumab pegol?
Certolizumab pegol (Cimzia) is a TNF-alpha inhibitor approved for multiple autoimmune disorders, including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and ankylosing spondylitis. The drug has been on the market since 2008, with ongoing research expanding its therapeutic scope.
Completed and Ongoing Clinical Trials
Data from ClinicalTrials.gov indicates over 100 trials involving certolizumab pegol globally. These trials evaluate efficacy, safety, dosing, and extended indications. Notable completed studies include:
- RA and Crohn's Disease: Confirming efficacy and safety over long-term use.
- Psoriasis: Demonstrating effectiveness in moderate-to-severe plaque psoriasis.
- Pregnancy and Breastfeeding: Evaluating maternal-fetal safety, given its minimal placental transfer.
Active studies involve:
- Ulcerative colitis: Trials exploring subcutaneous and intravenous formulations.
- Other indications: Including hidradenitis suppurativa and non-infectious uveitis.
Recent and Planned Trials
Recent trials focus on expanding indications:
- Axial spondyloarthritis: Phase 3 trials assessing efficacy.
- Pediatric Crohn’s Disease: Trials exploring safety in pediatric populations.
- Combination therapies: Assessing efficacy with other biologics or small molecules.
Most ongoing studies target enrollment completion by 2024–2025. Regulatory submissions for additional uses are anticipated contingent on positive trial outcomes.
How does the market for certolizumab pegol compare with similar drugs?
Market Size and Key Competitors
In 2022, the global anti-TNF biologics market was valued at approximately $29 billion and projected to grow at a CAGR of 7% through 2027. Certolizumab pegol accounts for roughly 8% of this market. Major competitors include:
| Drug |
Indications |
Market Share (2022) |
Approval Year |
Administration Route |
| Adalimumab (Humira) |
RA, psoriasis, Crohn’s, others |
40% |
2002 |
Subcutaneous |
| Infliximab (Remicade) |
RA, Crohn’s, ulcerative colitis |
20% |
1998 |
Intravenous |
| Etanercept (Enbrel) |
RA, psoriatic arthritis |
15% |
1998 |
Subcutaneous |
| Certolizumab pegol (Cimzia) |
RA, Crohn’s, psoriatic arthritis |
8% |
2008 |
Subcutaneous |
Certolizumab pegol’s unique PEGylation offers less placental transfer, making it potentially safer during pregnancy than other TNF inhibitors.
Pricing and Market Penetration
Pricing varies by geography and indication but generally ranges from $2,500 to $3,500 per month. Insurance coverage limits market penetration mainly to established autoimmune conditions with existing regulatory approval.
What are the projections for certolizumab pegol’s market in the coming years?
Market Growth Drivers
- Expansion of indications: Pending trial successes in ulcerative colitis, hidradenitis suppurativa, and pediatric populations.
- Orphan drug potential: For rarer autoimmune diseases with unmet needs.
- Pregnancy safety profile: Positions the drug as a preferred option for women planning pregnancy.
Market Challenges
- Biosimilar entry: Predicted biosimilar launches from 2025 in Europe and the US could reduce prices and market share.
- Competitive landscape: Dominance of adalimumab and infliximab limits growth.
- Convenience factors: Oral or less frequent dosing formulations still in development for the class.
Market Forecast (2023–2030)
Analysts project the global certolizumab pegol market to reach approximately $1.1 billion by 2030, assuming:
- 3–5% annual growth from current levels.
- New indications gaining approval and broadening patient populations.
- Biosimilar competition reducing prices by 20-30%.
Growth will be concentrated in Europe and North America, where regulatory approvals and insurance coverage are advanced.
Key regulatory developments influencing future outlook
- The European Medicines Agency (EMA) approved certolizumab pegol for psoriasis and Crohn's disease in 2022.
- The U.S. Food and Drug Administration (FDA) is reviewing supplemental Biologics License Applications (sBLAs) for ulcerative colitis and pediatric Crohn’s disease, with decisions expected by late 2023.
- Ongoing phase 3 trials for hidradenitis suppurativa aim for potential approval by 2026.
What are the strategic implications for stakeholders?
- Biotech and pharma firms should monitor trial results for expansion opportunities.
- Investors canevaluate certolizumab’s positioning around biosimilars and new indications.
- Healthcare providers may consider safety advantages during pregnancy; adoption depends on formal label updates.
Key Takeaways
- Certolizumab pegol has a well-established presence in autoimmune indications, with ongoing expansion efforts.
- Clinical trials continue to explore new uses, notably in ulcerative colitis and pediatric populations.
- The market is expected to grow due to indication expansion but faces pricing pressures from biosimilars.
- Regulatory approvals, especially for ulcerative colitis and psoriasis, could significantly influence growth.
- Competition remains fierce, notably from adalimumab and infliximab.
FAQs
1. What makes certolizumab pegol different from other TNF inhibitors?
Its PEGylation reduces placental transfer, making it potentially safer during pregnancy.
2. When are new indications for certolizumab pegol expected to receive approval?
Pending successful trials, regulatory decisions for ulcerative colitis and pediatric Crohn’s are expected by 2023–2025.
3. How will biosimilar competition affect certolizumab pegol’s market?
Biosimilar launches from 2025 could lower prices and reduce market share, especially in Europe and the US.
4. What is the primary market for certolizumab pegol?
The US and Europe account for about 75% of revenue, with growth driven by expanded indications.
5. Is certolizumab pegol being studied for indications beyond autoimmune diseases?
Current trials focus on autoimmune and inflammatory conditions; no substantial data on off-label or non-autoimmune uses.
Sources:
[1] ClinicalTrials.gov
[2] IQVIA, "Global Biologic Market," 2022
[3] Renub Research, "Anti-TNF Market," 2022
[4] EMA, "Approval and Regulatory Decisions," 2022
[5] FDA, "Biologics License Applications," 2023
